Sofinnova Partners closes oversubscribed €82 million MD Start IV fund to build new MedTech startups
Sofinnova Partners, a Paris-based life sciences investor, has closed its Sofinnova MD Start IV fund at €82 million. The firm said the fund was oversubscribed and will build on a strategy dating back to 2008 that has created around a dozen companies. “Sofinnova MD Start is one of the few strategies in Europe focused on […] The post Sofinnova Partners closes oversubscribed €82 million MD Start IV…
Sofinnova Partners, a Paris-based life sciences investor, has successfully closed its fourth MedTech-focused fund, Sofinnova MD Start IV, at €82 million. The oversubscribed fund expands upon a strategy pioneered in 2008 that has resulted in creating approximately a dozen companies. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, explained that the firm’s active role in building and supporting each company from inception sets their MedTech creation model apart.
With the fresh capital, Sofinnova Partners aims to scale this approach and solidify its role within the European life sciences value chain. Since its establishment in 1972, Sofinnova Partners has been a European venture capital firm specializing in healthcare and sustainability, operating across Paris, London, and Milan through a multi-fund platform of seven investment strategies.
Among their portfolio highlights are LimFlow, acquired by Inari Medical, and preCARDIA acquired by Abiomed. As part of their plan, Sofinnova Partners aims to create six to eight new MedTech companies across Europe and the US within the next five years, providing founders with capital and hands-on support to guide them through critical clinical and operational milestones.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
